Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s (AZN) fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate Breztri as a potential treatment for asthma. The trials evaluated the efficacy and safety of Breztri versus maintenance treatment with ICS/LABA in adults and adolescents with uncontrolled asthma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target lowered to 13,700 GBp at Morgan Stanley
- AstraZeneca considering moving more production to U.S., Pharmaphorum reports
- AstraZeneca: Strong Buy Rating Backed by Oncology Growth and Promising Pipeline
- AstraZeneca’s Strong EPS Performance and Strategic Developments Justify Buy Rating
- AstraZeneca Reports Strong Q1 2025 Growth